ECG exerts therapeutic benefits in ameliorating postmenopausal MS‐related metabolic disorders by inhibiting inflammatory responses, suppressing NLRP3 inflammasome activation, and modulating the PI3K/AKT1 signaling pathway, providing new insights into the application of ECG for managing postmenopausal MS. The gene discussed is AKT1; the disease is Other metabolic disease.